Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.

Conclusion: SG may represent a novel class of active drugs for carcinosarcomas patients overexpressing Trop-2. PMID: 32082489 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research